about
Treatment for fatigue in amyotrophic lateral sclerosis/motor neuron disease (ALS/MND)Treatment for sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosisTreatment for sialorrhea in people with motor neuron disease or amyotrophic lateral sclerosisMinocycline for amyotrophic lateral sclerosis or motor neuron diseaseThe legs at odd angles (Loa) mutation in cytoplasmic dynein ameliorates mitochondrial function in SOD1G93A mouse model for motor neuron disease.One universal common endpoint in mouse models of amyotrophic lateral sclerosis.Apoptosis in amyotrophic lateral sclerosis: a review of the evidence.Arimoclomol: a potential therapy under development for ALS.An over-oxidized form of superoxide dismutase found in sporadic amyotrophic lateral sclerosis with bulbar onset shares a toxic mechanism with mutant SOD1A mutation in dynein rescues axonal transport defects and extends the life span of ALS miceDefective axonal transport in motor neuron disease.The X-linked adrenoleukodystrophy (X-ALD) and oxidative stress.A(a)LS: Ammonia-induced amyotrophic lateral sclerosis.The impact on the family carer of motor neurone disease and intervention with noninvasive ventilation.Riluzole: what it does to spinal and brainstem neurons and how it does it.The natural history of motor neuron disease: assessing the impact of specialist care.Characterization of the caspase cascade in a cell culture model of SOD1-related familial amyotrophic lateral sclerosis: expression, activation and therapeutic effects of inhibition.Vacuolization correlates with spin-spin relaxation time in motor brainstem nuclei and behavioural tests in the transgenic G93A-SOD1 mouse model of ALS.Flaviviruses in motor neuron disease.Expression of vesicular glutamate transporters, VGLUT1 and VGLUT2, in cholinergic spinal motoneurons.Treatment of fatigue in amyotrophic lateral sclerosis/motor neuron disease.Service use and needs of people with motor neurone disease and their carers in Scotland.Looking for differences in copy number between blood and brain in sporadic amyotrophic lateral sclerosis.Living with motor neurone disease: lives, experiences of services and suggestions for changeA virtual user involvement forum for people living with motor neuron disease
P2860
Q24199017-9763CCC3-E858-466A-94E5-4A7132A49DDEQ24234650-DF502CC6-3A23-4E3C-BA6E-F5E1B4852D4CQ24243640-0BB06E68-3048-4A9C-8D31-E601BD75C929Q24243793-EEF731BA-7F7F-4BE7-B757-620C8664D839Q30435889-F238A405-1963-4045-80E3-94A5D30B54FCQ33936763-38CAE30A-FFD9-400A-BE5B-B939927DCAA1Q34352949-85C1D8AB-5E1B-4F27-8A73-1451D07BD8ABQ35014529-1BC970D5-39C4-41AA-BD68-3A32E2EAC6D3Q35882558-14C3DEFA-2F68-4C57-A6AD-C357008BE18CQ36321318-07660F59-FADF-4E8F-AB18-C36EDBDF1E93Q36723372-A2241B2C-2859-448A-B88A-D45FE636134DQ36743396-C07B62A6-85A7-45EB-9C9E-5966C52EB265Q37337058-CF9522C3-2DBD-4D5E-B228-F4BB4BCDE12EQ37404308-6EF98DC0-7424-49B3-BA36-148C3E7914B8Q38011003-6A42572A-A787-437E-989C-19D4AEBDE387Q38014082-5ADC051F-AD84-4450-8130-221E8F34A5DCQ40376012-BE51BA97-E43A-4876-B84E-158E8AF89BD0Q42631614-5AAB8998-1E64-4ABA-937C-5D8A626FBFF4Q42991370-DE1F951D-E1ED-4F43-8B65-E13809B47E10Q45067707-E3DFA06F-B015-415B-8133-B05FBFB1D8E3Q47224541-0B7BA69F-6AFA-4CFA-A63A-57FA60DF8507Q48669993-9CC21FAD-DF81-4F7A-AA06-DEFF9A3073BCQ48957797-3C49D261-2715-4C7A-9690-82FCAFE05BA0Q57495682-FB9FE696-757E-4B0A-8A58-04687CBFB33FQ57495765-0E797078-44DC-4235-BDC7-6F134F7EA283
P2860
description
1999 nî lūn-bûn
@nan
1999 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Motor neurone disease.
@ast
Motor neurone disease.
@en
type
label
Motor neurone disease.
@ast
Motor neurone disease.
@en
prefLabel
Motor neurone disease.
@ast
Motor neurone disease.
@en
P2860
P1433
P1476
Motor neurone disease
@en
P2093
P2860
P304
P356
10.1136/BMJ.318.7191.1118
P407
P577
1999-04-01T00:00:00Z